Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF).

The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) and subsequent adoption by the European Commission, recognizing both the seriousness of IPF and the need for new treatment options for patients living with this devastating disease.

IPF is a rare, progressive lung disease characterized by irreversible scarring of lung tissue, that leads to declining lung function and, ultimately, respiratory failure. Despite existing treatments, patients continue to face poor outcomes and limited therapeutic options.